The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | Current treatment approaches in ET and an insight into the SURPASS-ET trial
Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of current treatment strategies in essential thrombocythemia (ET), and further highlights the Phase III SURPASS-ET trial (NCT04285086), which is comparing anagrelide versus ropeginterferon alfa-2b in patients with ET. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
